Title:
QUINAZOLINE COMPOUND USED AS AXL INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2021/088787
Kind Code:
A1
Abstract:
Disclosed is a quinazoline compound used as an AXL inhibitor. The structure of the quinazoline compound is as shown in general formula (I), and the definition of each substituent is as described in the description. Further provided is a preparation method therefor. The quinazoline compound of the present invention has significant AXL inhibitory activity, and can be used as an AXL inhibitor.
Inventors:
LI DONGDONG (CN)
MA CHANGYOU (CN)
FENG HAIWEI (CN)
WU JIAN (CN)
XU DAN (CN)
ZHU CHUNXIA (CN)
TIAN ZHOUSHAN (CN)
MA CHANGYOU (CN)
FENG HAIWEI (CN)
WU JIAN (CN)
XU DAN (CN)
ZHU CHUNXIA (CN)
TIAN ZHOUSHAN (CN)
Application Number:
PCT/CN2020/126083
Publication Date:
May 14, 2021
Filing Date:
November 03, 2020
Export Citation:
Assignee:
NANJING CHIA TAI TIANQING PHARMACEUTICAL CO LTD (CN)
International Classes:
A61K31/497; C07D405/14; A61K31/5377; A61K31/5383; A61P35/00; A61P35/02; C07D405/12; C07D487/04; C07D513/04
Foreign References:
| CN108250200A | 2018-07-06 | |||
| CN107001335A | 2017-08-01 | |||
| CN109384774A | 2019-02-26 |
Other References:
LIU ZHIQING ET AL.: "Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities", ACS MEDICINAL CHEMISTRY LETTERS, vol. 5, no. 4, 8 February 2014 (2014-02-08), pages 304 - 308, XP055323982, DOI: 10.1021/ml400373j
Download PDF: